April 2005
Investment Dealers' Digest;4/18/2005, Vol. 71 Issue 15, p28
Trade Publication
The article presents statistical information on global healthcare underwriting volume as of April 11, 2005 and other developments in the pharmaceutical industry. An investor lawsuit was filed against GlaxoSmithKline PLC alleging it violated securities laws by issuing false or misleading statements. The complaint alleges that the drug company concealed information about the dangers of using its antidepressant Paxil to treat adolescent depression. Last summer, the FDA confirmed a link between Paxil, among other SSRI drugs, and suicidal tendencies in young people.


Related Articles

  • CNS News Round-Up.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p2 

    The article focuses on GlaxoSmithKline PLC (GSK), which has attempted to resolve the problems associated with its controversial depression drug Paxil. Europe's leading pharmaceuticals group has agreed to pay $2.5 million to settle a lawsuit filed by the New York Attorney General's office which...

  • GlaxoSmithKline settles Paxil litigation.  // PharmaWatch: CNS;October 2004, Vol. 3 Issue 10, p13 

    The article presents information about GlaxoSmithKline PLC (GSK), which has agreed to pay $2.5 million to settle a lawsuit filed by the New York Attorney General's office which alleged that the leading pharmaceuticals group failed to disclose data on the use of its blockbusting antidepressant...

  • GlaxoSmithKline faces US lawsuit over concealment of trial results. Dyer, Owen // BMJ: British Medical Journal (International Edition);6/12/2004, Vol. 328 Issue 7453, p1395 

    Reports on the lawsuit that the British pharmaceutical company GlaxoSmithKline is facing in the United States over alleged concealment of negative trial results involving its antidepressant paroxetine. Details of the lawsuit; Statement from GlaxoSmithKline; How the case has reignited debate in...

  • GSK Loses first Paxil Court Decision.  // Pharmaceutical Representative;Dec2009, Vol. 39 Issue 12, p8 

    The article reports that pharmaceutical company GlaxoSmithKline (GSK) will pay 2.5 million dollars in damages after a court decision in Philadelphia, Pennsylvania. GSK loses its battle against the court to testify that its antidepressant drug Paxil leads to birth defects and will pay 2.5 million...

  • GlaxoSmithKline Accused of Fraud: Settlement Reached.  // HealthFacts;Sep2004, Vol. 29 Issue 9, p2 

    Reports on a settlement reached for a lawsuit against GlaxoSmithKline, one of the world's largest pharmaceutical companies as of September 2004. Specifics of the charges filed against GlaxoSmithKline; Cost of the settlement fee agreed upon in the case; Reason for the allotted period given to...

  • IP litigation in China could drive innovation. Jia, Hepeng // Nature Biotechnology;Apr2004, Vol. 22 Issue 4, p368 

    Presents a report on the rising numbers of intellectual property (IP) rights litigation cases between international pharmaceutical companies and their Chinese rivals that could incentivize China's biotech sector. Example of the case of GlaxoSmithKline (London) stopping Chinese drugmakers from...

  • High court to rule on overtime pay. GREENWALD, JUDY // Business Insurance;12/5/2011, Vol. 45 Issue 47, p4 

    The article focuses on the decision of the U.S. Supreme Court to review a case concerning overtime pay of pharmaceutical sales representatives. It makes reference to February decision by the 9th U.S. Circuit Court of Appeals that exempting these sales representatives from GlaxoSmithKline PLC...

  • Big Pharma Smells Parallel Trade Victory. Miller, Edward // Pharmaceutical Technology Europe;Mar2005, Vol. 17 Issue 3, p14 

    The article reports that European Court's decision on parallel trade set to save Big Pharmaceuticals £3.5 billion. The opinion delivered by the Advocate General of the European Court in a case against the company GSK brought by the Greek Competition Commission may hand a major victory to drug...

  • Bird flu bungle. Ferguson, Adele // BRW;3/16/2006, Vol. 28 Issue 10, p12 

    The article reports on the lawsuit filed against GlaxoSmithKline PLC (GSK) by Australian-based Biota Holdings. Biota sues GSK for 430 million dollars in damages in relation to a licensing agreement between the two companies involving the flu drug Relenza. The filing of Biota's case was based on...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics